CollaGenex, QuatRx Agree To Develop Topical Psoriasis Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
CollaGenex tells “The Pink Sheet” DAILY it expects to launch becocalcidiol for treatment of psoriasis between late 2010 and early 2012.
You may also be interested in...
Anacor’s Topical Psoriasis Candidate Produces Strong Showing In Phase II
Boron-based anti-inflammatory drug targets TNF-a, other cytokine receptors.
Anacor’s Topical Psoriasis Candidate Produces Strong Showing In Phase II
Boron-based anti-inflammatory drug targets TNF-a, other cytokine receptors.
Galderma Acquires CollaGenex For $420 Million
Swiss firm fattens dermatological portfolio with acquisition.